{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Kaplan and Meier product limit methods will be used to estimate the median PFS with 95% confidence intervals. Furthermore, the univariate and multivariate Cox proportional hazards regression model will be used to identify prognostic factors for PFS.","groups":[{"description":"Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)","id":"OG000","title":"Tivantinib Treatment"}],"populationDescription":"No participants responded to the therapy and no analyses was done.","reportingStatus":"POSTED","timeFrame":"From start of the treatment to disease progression or death (regardless of cause of death), whichever comes first, assessed up to 30 days","title":"Progression-free Survival (PFS)","type":"OTHER_PRE_SPECIFIED"}